TherapeuticsMD Announces Closing of Its Underwritten Public Offering of Common Stock
October 29 2019 - 4:05PM
Business Wire
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the closing
of its underwritten public offering of 29,900,000 shares of its
common stock at a price to the public of $2.75 per share, inclusive
of the underwriters’ option to purchase additional shares of common
stock, which option was exercised in full. TherapeuticsMD received
net proceeds from the offering of approximately $77.0 million,
after deducting underwriting discounts and commissions and
estimated offering expenses payable by TherapeuticsMD. All of the
shares in the offering were sold by TherapeuticsMD.
J.P. Morgan acted as sole bookrunning manager for the offering.
Stifel acted as lead manager for the offering.
TherapeuticsMD intends to use the proceeds of the offering for
commercialization of its three FDA-approved products, IMVEXXY®
(estradiol vaginal inserts) for the treatment of moderate-to-severe
dyspareunia (vaginal pain associated with sexual activity), a
symptom of vulvar and vaginal atrophy due to menopause, BIJUVA®
(estradiol and progesterone) capsules, a hormone therapy
combination of bio-identical 17ß-estradiol and bio-identical
progesterone in a single, oral softgel capsule, for the treatment
of moderate-to-severe vasomotor symptoms due to menopause in women
with a uterus, and ANNOVERA™ (segesterone acetate/ethinyl estradiol
vaginal system), the first and only patient-controlled,
procedure-free, reversible prescription contraceptive that can
prevent unintended pregnancy for up to a full year, including to
maximize ANNOVERA’s consumer-focused commercialization strategy,
and for general corporate purposes.
TherapeuticsMD has filed a shelf registration statement on Form
S-3 with the Securities and Exchange Commission (the “SEC”) with
respect to the offering that became effective upon filing. A
preliminary prospectus supplement and accompanying prospectus
related to the offering were filed with the SEC on October 23,
2019. A final prospectus supplement and accompanying prospectus
relating to the offering were filed with the SEC on October 25,
2019.
TherapeuticsMD’s SEC filings are available to the public from
the SEC’s website at www.sec.gov. Copies of the final prospectus
supplement and the accompanying prospectus relating to the offering
may also be obtained by contacting J.P. Morgan Securities LLC,
Attention: Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, or by telephone at 1-866-803-9204, or by email
at prospectus-eq_fi@jpmchase.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be
any sale of these securities in any state or other jurisdiction in
which such offer, solicitation, or sale would be unlawful prior to
the registration or qualification under the securities laws of any
such state or other jurisdiction.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative, leading healthcare
company, focused on developing and commercializing novel products
exclusively for women. Our products are designed to address the
unique changes and challenges women experience through the various
stages of their lives with a therapeutic focus in family planning,
reproductive health, and menopause management. The company is
committed to advancing the health of women and championing
awareness of their healthcare issues.
Forward-Looking Statements
This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include,
but are not limited to, statements relating to TherapeuticsMD’s
objectives, plans and strategies as well as statements, other than
historical facts, that address activities, events or developments
that TherapeuticsMD intends, expects, projects, believes or
anticipates will or may occur in the future. These statements are
often characterized by terminology such as “believes,” “hopes,”
“may,” “anticipates,” “should,” “intends,” “plans,” “will,”
“expects,” “estimates,” “projects,” “positioned,” “strategy” and
similar expressions and are based on assumptions and assessments
made in light of management’s experience and perception of
historical trends, current conditions, expected future developments
and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this
press release, and the company undertakes no duty to update or
revise any such statements, whether as a result of new information,
future events or otherwise. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties, many of which are outside of the company’s control,
that may cause actual results to differ materially, including the
risks and uncertainties associated with market conditions, risks
and uncertainties associated with TherapeuticsMD’s business and
finances in general and other risks described in the sections
titled “Risk Factors” in TherapeuticsMD’s filings with the SEC,
including its most recent Annual Report on Form 10-K, the
preliminary and final prospectus supplements with respect to the
offering and other filings with the SEC.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191029005761/en/
Investor Contact Nichol Ochsner Vice President Investor
Relations 561-961-1900 Ext. 2088 nochsner@TherapeuticsMD.com
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
TherapeuticsMD (NASDAQ:TXMD)
Historical Stock Chart
From Sep 2023 to Sep 2024